Loading financials from SEC filings…
Biotechnology · Healthcare · Fiscal year ends Dec 31
Net income was −$230M. Operating cash flow of −$136M less capital expenditure of $506,000 left free cash flow of −$137M.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Research & development | 217 | 268 | 206 | 126 | 182 |
| Operating income | −267 | −341 | −277 | −187 | −234 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | −267 | −334 | −260 | −176 | −230 |
| Income tax | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 |
| Net income | −267 | −334 | −260 | −176 | −230 |
| Diluted EPS | −5.16 | −6.39 | −4.97 | −3.35 | −4.32 |
| Diluted shares | 51.8 | 52.2 | 52.4 | 52.6 | 53.2 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 732 | 190 | 286 | 168 | 210 |
| Current assets | 735 | 486 | 289 | 172 | 215 |
| Net PP&E | 41.3 | 56.4 | 120 | 102 | 85.3 |
| Total assets | 904 | 667 | 479 | 336 | 352 |
| Payables | 12.4 | 9.1 | 13.6 | 3.9 | 12.9 |
| Current liabilities | 64.7 | 52.5 | 41.7 | 25.6 | 45.5 |
| Total liabilities | 241 | 230 | 214 | 185 | 194 |
| Shareholders' equity | 663 | 436 | 266 | 150 | 157 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −182 | −206 | −154 | −117 | −136 |
| Capital expenditure | 17.0 | 37.0 | 41.4 | 0.4 | 0.5 |
| Free cash flow | −199 | −243 | −196 | −118 | −137 |
| Depreciation & amortisation | 1.0 | 3.8 | 18.3 | 18.7 | 18.3 |
| Stock-based compensation | 61.4 | 106 | 88.6 | 60.2 | 58.9 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −40.3% | −76.5% | −98.0% | −117.2% | −146.1% |
| ROCEEBIT ÷ (assets − current liabilities) | −31.8% | −55.6% | −63.4% | −60.3% | −76.6% |
| Cash conversion (CFO ÷ net income) | 0.68x | 0.62x | 0.59x | 0.67x | 0.59x |
| Interest cover | −5682x | −18966x | −21332x | – | – |
| Current ratio | 11.4x | 9.26x | 6.93x | 6.72x | 4.72x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.